Page 291 - Vitamin D and Cancer

278 R. Okamoto et al.

154. Norman AW, Manchand PS, Uskokovic MR, Okamura WH, Takeuchi JA, Bishop JE,
Hisatake JI, Koeffler HP, Peleg S (Jul 13, 2000) Characterization of a novel analogue of
lalpha,25(OH)(2)-vitamin D(3) with two side chains: interaction with its nuclear receptor
and cellular actions. J Med Chem 43(14):2719–30
155. O’Kelly J, Uskokovic M, Lemp N, Vadgama J, Koeffler HP (Aug, 2006) Novel
Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signal-
ing pathway. J Steroid Biochem Mol Biol 100(4–5):107–16
156. Mellibovsky L, Díez A, Pérez-Vila E, Serrano S, Nacher M, Aubía J, Supervía A, Recker RR
(Mar, 1998) Vitamin D treatment in myelodysplastic syndromes. Br J Haematol
100(3):S16–20
157. Molnár I, Stark, Lovato J, Powell BL, Cruz J, Hurd DD, Mathieu JS, Chen TC, Holick MF,
Cambra S, McQuellon RP, Schwartz GG (May, 2007) Treatment of low-risk myelodysplastic
syndromes with high-dose daily oral cholecalciferol (2000–4000 IU vitamin D(3)).
Leukemia 21(5):1 089–92